SEC Form 4/A · accession 0001013606-16-000307
ENDOLOGIX INC /DE/ · ELGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Michael V. Chobotov
Officer — Chief Technology Officer
Period of report
Feb 3, 2016
Accepted (ET)
Sep 26, 2016 · 11:03 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001013606
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Feb 3, 2016 | A | 116,948 | $7.42 | A | 203,269 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Due to an administrative error, the initial Form reflected a transaction date of February 29, 2016. However, the transaction date should have been February 3, 2016, the effective date of the merger of TriVascular Technologies, Inc. ("TriVascular") with the Issuer and the date on which the Reporting Person was deemed to receive the shares.
- F2The Reporting Person received the shares in exchange for shares of TriVascular common stock pursuant to the merger of TriVascular with the Issuer. Pursuant to the terms of the merger agreement each share of TriVascular common stock automatically converted into the right to receive 0.631 shares of common stock of the Issuer. On the effective date of the merger, the closing price of the Issuer's common stock was $7.42.